Insulin Lispro

Research summary

In healthy human subjects, Insulin Lispro has been studied mainly to characterize pharmacokinetics, pharmacodynamics, and safety. These studies consistently show that Insulin Lispro is absorbed more quickly than regular human insulin, achieves a higher early insulin concentration, and produces a faster onset of glucose‑lowering effect, with similar overall potency but a shorter duration of action. These properties underpin its widespread use as a mealtime insulin in people with diabetes, enabling dosing closer to food intake and more physiological postprandial glucose control. In clinical trials involving individuals with diabetes, Insulin Lispro generally provides equal or better glycemic control than regular human insulin, particularly with respect to postprandial glucose levels, and may reduce the risk of severe hypoglycemia in some regimens. Safety data from both healthy volunteers and diabetic patients indicate that adverse effects are typical of insulin therapy: mainly hypoglycemia and injection‑site reactions, with rare systemic allergic responses. There is no evidence that Insulin Lispro confers health benefits for non‑diabetic, otherwise healthy individuals beyond its glucose‑lowering action, and it should be regarded as a prescription medication rather than a general supplement.